| abstract |
METHODS OF ADMINISTERING ANTI-TNFca ANTIBODIES Abstract Methods of treating disorders in which TNFa activity is detrimental via s biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a(hTNFa) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFa (e.g., Kd = 10-8 M or less), a slow off rate for hTNFa dissociation (e.g., Kf = 10S ec or less) and neutralize hTNFaX activity in vitro 10 and in vivo. An antibody of the invention can be a full-length antibody or an antigen binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention. |